• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bayer A G Ord (OP:BAYZF)

52.79 +2.76 (+5.52%)
Delayed Quote Updated: 11:26 AM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 212
Open 52.79
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 50.03
Today's Range 52.79 - 52.79
52wk Range 30.00 - 61.38
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Bayer to Invest 2.2 Billion U.S. Dollars in a New Manufacturing Site in the United States
October 02, 2026
From Bayer
Via Business Wire
News headline image
Alka-Seltzer Plus® to Relaunch as Alka-Seltzer™ Cold in 2026, Bringing Simpler Shopping and More Value to the Cough/Cold Aisle
October 01, 2026
From Bayer
Via Business Wire

Performance

52-Week Range 14.0% below 52-week high
52.79
30.0052W Low 61.3852W High
1 Week 8.3% below 1-week high
50.031W Low 57.601W High

Bayer A G Ord (BAYZF) traded between $30.00 and $61.38 over the past 52 weeks and last traded at $52.79, 14.0% below its 52-week high. Over the past week it ranged between $50.03 and $57.60.

Past 12 Months
-8.3%
-6.6%
-9.8%
+11.3%
+17.5%
+54.9%
1W -$4.81
1M -$3.71
3M -$5.76
6M +$5.34
YTD +$7.86
1Y +$18.71

BAYZF was +54.9% over the past year, +11.3% over six months, +17.5% year to date, -8.3% in the last week.

12 Months vs Market
BAYZF
+54.9%
DIA
+9.9%
SPY
+15.0%
QQQ
+23.7%
IWM
+15.4%

Over the past 12 months BAYZF returned +54.9% versus DIA (Dow) +9.9%, SPY (S&P 500) +15.0%, QQQ (Nasdaq 100) +23.7% and IWM (Russell 2000) +15.4%.

Volume & Liquidity 0.04× 3-mo avg
Today 212 3-mo avg 5.8K
1W
828.0
1M
7.4K
3M
5.8K
6M
4.5K
YTD
5.4K
1Y
5.1K

BAYZF most recently traded 212 shares against a 3-month average daily volume of 5.8K.

More News

Read More
News headline image
MiraSOFT™ Launch at CVS Pharmacy, Expanding the MIRA Portfolio with a Stool Softener Option
September 29, 2026
From Bayer
Via Business Wire
News headline image
U.S. FDA Accepts sNDA and Grants Priority Review to Bayer’s Lynkuet® (elinzanetant) for a New Indication for the Treatment of Moderate to Severe Vasomotor Symptoms Due to Endocrine Therapy Related to Breast Cancer
September 28, 2026
From Bayer
Via Business Wire
News headline image
Robigo and Leaps by Bayer Announce Series A Financing to Advance Engineered Biologicals That Protect Yields and Reduce Costs
September 17, 2026
From Bayer
Via Business Wire
News headline image
Bayer’s KERENDIA® (finerenone) Receives FDA Approval as the First New Treatment in 30 Years for Adults with Chronic Kidney Disease (CKD) and Type 1 Diabetes
September 17, 2026
From Bayer
Via Business Wire
News headline image
Bayer Launches Nationwide Science Delivers Tour to Take Science on the Road
September 10, 2026
From Bayer
Via Business Wire
News headline image
U.S. FDA Grants Accelerated Approval to Bayer’s HYRNUO® (sevabertinib) as a First-Line Targeted Therapy for Patients with HER2-Mutated Non-Small Cell Lung Cancer
September 09, 2026
From Bayer
Via Business Wire
News headline image
BAYER INITIATES PHASE II STUDY OF INVESTIGATIONAL GIRK4 INHIBITOR IN PATIENTS WITH ATRIAL FIBRILLATION
September 09, 2026
From Bayer
Via Business Wire
News headline image
Bayer Announces Phase III REVEAL Study with Investigational PET Radiotracer Iodine 124 Evuzamitide Presented as Late-Breaker at ESC 2026
August 30, 2026
From Bayer
Via Business Wire
News headline image
Bayer to Present New Phase III Data from Its Cardiovascular, Kidney, and Stroke Clinical Trial Programs at ESC 2026
August 20, 2026
From Bayer
Via Business Wire
News headline image
One A Day® Introduces New Women's Multi Gummy Formula with 1,000 mcg Biotin
July 28, 2026
From Bayer
Via Business Wire
News headline image
New Economist Enterprise Research Highlights Why Integrating Self-Care Into Health Systems Matters
July 23, 2026
From Bayer
Via Business Wire
News headline image
Bayer and Henry Ford Health Announce Strategic Research Partnership to Expand Patient Access to Clinical Trials
July 17, 2026
From Bayer
Via Business Wire
News headline image
Sabanto and Leaps by Bayer Announce Oversubscribed Series B Financing to Scale Autonomous Technology for Row Crop Farming
July 14, 2026
From Bayer
Via Business Wire
News headline image
The University of Colorado Anschutz, along with UCHealth and Children’s Hospital Colorado, Form Strategic Alliance with Bayer to Advance Drug Development and Clinical Trials
July 07, 2026
From Bayer
Via Business Wire
News headline image
Luke Bryan and One A Day® Launch Limited Edition Multivitamin Bottles Available Only at Walmart
July 02, 2026
From Bayer
Via Business Wire
News headline image
Bayer Group to Consolidate U.S. Glyphosate Business Into Distinct Entity Operating as Ruveon
July 01, 2026
From Bayer
Via Business Wire
News headline image
Bayer and Iambic Collaborate to Advance Drug Discovery with AI
June 22, 2026
From Bayer
Via Business Wire
News headline image
Bayer Completes Acquisition of Perfuse Therapeutics
June 17, 2026
From Bayer
Via Business Wire
News headline image
Aleve® Launches its Project DIY Campaign with HGTV Stars Dave & Jenny Marrs to Highlight Hardworking Hobbyists and Long-Lasting Pain Relief
June 16, 2026
From Bayer
Via Business Wire
News headline image
Bayer’s AMBELVIST® (gadoquatrane) Receives FDA Approval for Contrast-Enhanced MRI to Detect and Visualize Lesions with Abnormal Vascularity in the Central Nervous System and Non-CNS Body Regions
June 15, 2026
From Bayer
Via Business Wire
News headline image
Dr. Jost Reinhard Appointed President of Bayer’s Radiology Business
June 09, 2026
From Bayer
Via Business Wire
News headline image
Bayer Announces Global Consumer Health Leadership Changes to Accelerate Growth
June 08, 2026
From Bayer
Via Business Wire
News headline image
Phase III FIND‑CKD Results Show Bayer’s KERENDIA® (finerenone) Improved eGFR Slope and Reduced Risk of a Composite Kidney-Cardiovascular Outcome in Adults with Non‑Diabetic Chronic Kidney Disease
June 05, 2026
From Bayer
Via Business Wire

Frequently Asked Questions

Is Bayer A G Ord publicly traded?
Yes, Bayer A G Ord is publicly traded.
What exchange does Bayer A G Ord trade on?
Bayer A G Ord trades on the OTC Traded
What is the ticker symbol for Bayer A G Ord?
The ticker symbol for Bayer A G Ord is BAYZF on the OTC Traded
What is the current price of Bayer A G Ord?
The current price of Bayer A G Ord is 52.79
When was Bayer A G Ord last traded?
The last trade of Bayer A G Ord was at 10/02/26 11:26 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap